ACURA PHARMACEUTICALS, INC: debt financing — Acura Pharma gets $300K more loans from AD Pharma, warns of possible shutdown if no financing by March 2026

ACURA PHARMACEUTICALS, INC

Received $100,000 loans on Feb 6, Feb 13, and Mar 9, 2026 from Abuse Deterrent Pharma, LLC (AD Pharma), increasing principal balance to $9,894,279.
Note bears interest at 5.25% per annum, with overdue amounts accruing at 7.5%; events of default include bankruptcy, payment failure, and admitted inability to pay debts.
AD Pharma directly owns approximately 65% of Acura's outstanding common stock as of Feb 28, 2026, and is controlled by Mr. Schutte.
If additional financing is not secured by end of March 2026, Acura will need to scale back operations, including furloughs and layoffs, or terminate operations and seek bankruptcy protection.
No assurance of receiving more funds; failure could result in complete loss of shareholder value.

item 1.01 item 2.01 item 2.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

ACURA PHARMACEUTICALS, INC incurred loan of $100,000 with Abuse Deterrent Pharma, LLC at 5.25%.

Instrument: loan
Principal: $100,000
Counterparty: Abuse Deterrent Pharma, LLC
Rate: 5.25%
Event: incurrence

Exact text from the filing

On each of February 6, 2026, February 13, 2026 and March 9, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (“AD Pharma”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ACURA PHARMACEUTICALS, INC entered into Note with Abuse Deterrent Pharma, LLC valued at $100,000 (effective 2026-02-06).

Action: entry
Agreement: credit facility
Counterparty: Abuse Deterrent Pharma, LLC
Value: $100,000
Effective: 2026-02-06

Exact text from the filing

On each of February 6, 2026, February 13, 2026 and March 9, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC ("AD Pharma").

View on SEC.gov

311 debt financings filed in the last 30 days. Browse all debt financings →

Source: SEC EDGAR

accession 0001104659-26-025901

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.